Clinical trials: Recurrence
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Intrahepatic Cholangiocarcinoma
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study .
- Trial name
- NCT04295317
- Testing
- PD-1 blocking antibody SHR-1210, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Myeloma
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control multiple myeloma (MM).
- Trial name
- NCT02114502
- Testing
- Carfilzomib, SAHA, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukaemia Recurrent, Chronic Myeloid Leukemia, in Relapse
Myeloid Mutations Register in R/R CML
The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.
- Trial name
- NCT05080829
- Testing
- Myeloid mutations measurement
- Where
- Mexico
- Volunteers
- 29 people
- Sponsor
- Grupo Cooperativo de Hemopatías Malignas
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT00884767
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Institut Cancerologie de l'Ouest
Endometrial Cancer, Endometrial Carcinoma (EC)
Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer
This multicenter retrospective observational cohort study aims to evaluate the prognosis of patients with non-myoinvasive endometrial cancer harbouring high-risk molecular features by determining the rate of lymph node…
- Conditions
- Endometrial Cancer, Endometrial Carcinoma (EC), p53abn
- Trial name
- MyoNone (NCT07838207)
- Where
- Spain
- Volunteers
- 350 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, Recurrent Glioblastoma
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent).
- Trial name
- NCT05557292
- Testing
- RMC-5552
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Nicholas Butowski
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Recurrent Patellar Dislocation, Patellar Instability
Evaluation of Adductor Magnus Tenodesis in Patients With Recurrent Patellar Dislocation.
Between 2010 and 2012, 33 children and adolescents (39 knees) with recurrent patellar dislocation were treated with MPFL reconstruction using the adductor magnus tendon.The aim of the study is to assess the effectiveness of this…
- Conditions
- Recurrent Patellar Dislocation, Patellar Instability, Patellofemoral Osteoarthritis
- Trial name
- NCT05184439
- Testing
- Adductor magnus tenodesis for recurrent patellar dislocation
- Where
- Poland
- Volunteers
- 22 people
- Sponsor
- Polish Mother Memorial Hospital Research Institute
Recurrent Pulmonary Embolism (Disorder)
A Random Selection of Patients From the SENTRY Study Who Have a Bioconverted Sentry IVC Filter in Situ With a Minimum Dwell Time of 24 Months From a Single Center Follow up
IVUS Evaluation of the Bioabsorbable Sentry IVC Filter 3-5 Years Post Deployment Follow up
- Trial name
- NCT04208139
- Testing
- IVUS
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NC Heart and Vascular Research, LLC
Other Instability, Shoulder, Dislocations
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs.
- Conditions
- Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
- Trial name
- MOONSI (NCT02075775)
- Where
- 11 sites in United States
- Volunteers
- 1,733 people
- Sponsor
- Carolyn M Hettrich
Breast Cancer
Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving a vaccine with Montanide ISA-51 and sargramostim may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00079157
- Testing
- incomplete Freund's adjuvant, sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0)
Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac
Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled…
- Conditions
- Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0), Mediastinal Lymph Node Recurrence From All Types of Primary Cancer, Pulmonary Node Recurrence From All Types of Primary Cancer
- Trial name
- LIN-LUNG-2504 (NCT07733219)
- Testing
- MRI-LINAC radiotherapy
- Volunteers
- 59 people
- Sponsor
- Centre Oscar Lambret
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and…
- Conditions
- Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
- Trial name
- NCT02962167
- Testing
- Modified Measles Virus, Modified Measles Virus Lumbar Puncture
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sabine Mueller, MD, PhD
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Lymphocytic Leukemia
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes.
- Trial name
- NCT00935792
- Testing
- alemtuzumab, everolimus
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic